Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location |
|---|---|---|---|
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa |
Hidradenitis Suppurativa | Phase 2 | United States France Spain Germany Belgium Hungary Austria View All |
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS |
Relapsing Multiple Sclerosis | Phase 3 | United States Hungary Poland Turkey Bulgaria View All |
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML |
FLT3-mutated Acute Myeloid Leukemia | Phase 2 | Turkey Jordan Germany Italy Czech Republic Poland Slovenia Korea, Republic of Austria View All |
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients |
Sickle Cell Disease (SCD) | Phase 2 | United States Turkey Spain Lebanon Germany Belgium Colombia United Kingdom Italy Oman Brazil View All |
Dabrafenib and/or Trametinib Rollover Study |
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma | Phase 4 | United States Spain Hungary |
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors |
Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma | Phase 1 | United States Netherlands Spain Japan Italy Korea, Republic of Singapore Taiwan Canada View All |
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone |
Advanced Solid Tumors Which Are cMET-dependent | Phase 2 | United States Germany Belgium Italy Korea, Republic of Singapore View All |
Ribociclib (LEE011) Rollover Study for Continued Access |
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | Phase 2 | Taiwan United States |
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study |
ALK Positive Malignancies | Phase 4 | Brazil China France |
CAR-T Long Term Follow Up (LTFU) Study |
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Phase 3 | United States Spain Germany Australia Japan Denmark Belgium Canada Finland United Kingdom Italy Norway France Israel Singapore Taiwan Austria View All |